晶澳科技(002459.SZ):擬投資102.9億元建曲靖10GW高效電池、5GW組件項目及合肥11GW高功率組件改擴建項目
格隆匯5月18日丨晶澳科技(002459.SZ)公佈,根據公司戰略發展需求,公司擬對公司一體化產能進行擴建。其中,曲靖10GW高效電池、5GW組件項目,項目總投資606,219.66萬元(含流動資金),建設週期預計24個月;合肥11GW高功率組件改擴建項目,項目總投資422,750萬元(含流動資金),項目建設週期預計28個月。
上述項目的投資建設符合公司未來產能規劃的戰略需要,有利於公司垂直一體化的產業鏈佈局。項目投產後,能夠有效提高高效產品的產能,滿足市場對高效產品的需求,不斷提高市場份額和一體化盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.